Sign in
TerminatedPhase 2

Does Oxytocin Alter Tolerance to or Motivation for Alcohol

Key facts

Who runs it
Indiana University
Where
Indianapolis, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
6 people enrolled
Started
16 Jan 2022
Ended
21 Dec 2023
Type of study
Interventional, 2 groups
Treatments tested
  • Intranasal oxytocin
  • Intranasal placebo
Record updated
4 March 2025
Why it stopped
Due to complications delaying the availability of the intranasal oxytocin and IV alcohol solutions needed for this project, we were unable to complete subjects in the self-administration arm of this study.

Who can take part

Age
21 years to 60 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Heavy alcohol drinkers
  • Able to understand/complete questionnaires and procedures in English
  • Have venous access sufficient to allow blood sampling

Who cannot take part

  • Positive urine drug screen for amphetamines/ methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine if determined by the PI to adversely affect participant safety or data integrity
  • Medications (past 30 days) that could influence participant safety or data integrity (e.g. antidepressants, antipsychotics, benzodiazepines, etc.) as determined by the PI
  • Latex allergy
  • Nasal condition that compromises delivery and/or absorption of intra-nasal oxytocin
  • Desire to be treated for any substance use disorder or court ordered to not drink alcohol
  • Medical disorders or other conditions such as alcohol withdrawal seizures or delirium tremens that may influence study outcome or participant safety
  • DSM 5 Disorders (other than alcohol) or current/history of neurological disease of cerebral origin, or head injury with > 20 min loss of consciousness, if determined by the PI to affect participant safety or data integrity
  • Any condition for which the PI and investigative team determine it is unsafe or not prudent to enroll a participant
  • Pregnant or breast-feeding women
  • Positive breath alcohol reading at beginning of the experimental session
  • Actively suicidal (for example, any current suicidal intent, including a plan) or are at serious suicidal risk, by clinical judgment of the PI

Where in United States

  • University HospitalIndianapolis, United States

About the trial

What the trial wants to find out

This pilot study is intended to demonstrate feasibility and acquire preliminary data. If successful, this data could support a future project studying the effect of oxytocin on tolerance and alcohol seeking in humans.

The 2 groups in the trial

  • ClampTreatment being tested

    Repeated subjective and cognitive tests during a 4 hour session that includes a baseline period, an oxytocin or placebo delivery, absorption and testing period, and a 2 hour alcohol clamp. Oxytocin or placebo were delivered intranasally in two sessions, scheduled 3-4 weeks apart, double blind.

    Treatment: Intranasal oxytocin and Intranasal placebo

  • Progressive work for alcoholTreatment being tested

    Progressive work alcohol exposure, 2 sessions (intranasal oxytocin or placebo), double blind. Note this Arm was not completed (see Overall Status for explanation of study termination)

    Treatment: Intranasal oxytocin and Intranasal placebo

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Does Oxytocin Alter Tolerance to Alcohol or Motivation for Alcohol in Heavy Drinking Human Subjects: Testing a Novel Anti-Addiction Mechanism
Record updated
4 March 2025